Zentalis Pharmaceuticals, Inc. reports developments in clinical-stage oncology focused on azenosertib, an investigational WEE1 inhibitor being developed as a biomarker-driven treatment approach for ovarian cancer. Company updates commonly address Cyclin E1-positive platinum-resistant ovarian cancer, the DENALI, ASPENOVA and MUIR clinical programs, and scientific presentations involving ovarian cancer and triple-negative breast cancer research.
ZNTL news also includes financial results and operational updates, FDA-related clinical and regulatory disclosures, equity inducement grants under Nasdaq rules, and governance matters tied to the company’s public-company status.
Zentalis Pharmaceuticals (ZNTL) granted stock options to purchase 62,000 common shares to three newly hired employees on October 1, 2026.
The awards were made under the 2022 Employment Inducement Incentive Award Plan pursuant to Nasdaq Listing Rule 5635(c)(4). The exercise price is $2.605 per share, equal to the stock’s closing price on the grant date. The options have a 10-year term and vest over four years: 25% on the first anniversary of the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the next three years. Vesting requires continued service on each vesting date.
Zentalis Pharmaceuticals (ZNTL) will participate in two upcoming healthcare investor conferences in September 2026. Management will join a fireside discussion at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 8, 2026 at 4:30 p.m. ET, and deliver a company presentation at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14, 2026 at 2:35 p.m. ET.
Live webcasts and archived recordings of both events will be available on the Investors & Media section of the company’s website under “Events & Presentations.” Zentalis focuses on developing azenosertib, an investigational first-in-class WEE1 inhibitor for ovarian cancer and multiple tumor types.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) granted non-qualified stock options to purchase an aggregate of 269,000 shares of common stock to four newly hired employees on September 1, 2026. According to Zentalis, the awards were issued under its 2022 Employment Inducement Incentive Award Plan in line with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $3.71 per share, equal to the closing price on the grant date, and a 10-year term. Vesting occurs over four years: 25% on the first anniversary of the vesting commencement date, then the remaining 75% in equal monthly installments over the following three years, subject to continued service.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) closed its previously announced underwritten public offering of 26,450,000 common shares, including 3,450,000 from the underwriters’ fully exercised option. Shares were priced at $3.50, generating approximately $92.6 million in gross proceeds before fees and expenses.
According to the company, all shares were issued by Zentalis. The company plans to use net proceeds, together with existing cash and marketable securities, to fund clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostic work, pre-commercial activities, capital expenditures, working capital and other general corporate purposes.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) priced an underwritten public offering of 23,000,000 common shares at $3.50 per share, for expected gross proceeds of approximately $80.5 million before fees. All shares are offered by the company, with closing expected on August 17, 2026, subject to customary conditions.
Zentalis granted underwriters a 30-day option to purchase up to 3,450,000 additional shares at the public offering price, less discounts and commissions. According to Zentalis, net proceeds plus existing cash will fund clinical and preclinical work, regulatory filings, manufacturing, companion diagnostics, pre-commercial activities, and general corporate purposes.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has commenced a proposed underwritten public offering of common stock and, for certain investors, pre-funded warrants as an alternative to common shares. All securities will be issued and sold by the company, which expects to grant underwriters a 30-day option to purchase up to an additional 15% of common shares on the same terms.
According to Zentalis, net proceeds, combined with existing cash and marketable securities, are intended to fund clinical and preclinical development of its WEE1 inhibitor azenosertib and other programs, regulatory filings, manufacturing, companion diagnostic work, pre-commercial activities, capital expenditures, working capital and general corporate purposes. TD Cowen, Guggenheim Securities and Oppenheimer & Co. are joint bookrunners. The offering will be made under an effective SEC shelf registration statement.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported second quarter 2026 results and clinical updates centered on its investigational WEE1 inhibitor azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Following a Type D FDA meeting, the agency raised no objections to the continued study of the 400mg QD 5:2 monotherapy dose and acknowledged that the DENALI Part 2 population, including Part 2c, may support an accelerated approval pathway, subject to data strength and future treatment landscape.
Enrollment in DENALI Parts 2a and 2b is complete and Part 2c is enrolling, with an integrated topline readout expected in 1H 2027. The ASPENOVA Phase 3 confirmatory trial has dosed its first patient and is enrolling approximately 420 patients. The company reported cash, cash equivalents and marketable securities of $174.6 million as of June 30, 2026, which it believes will fund operations into late 2027. Second quarter 2026 research and development expenses were $35.2 million, total operating expenses were $44.4 million, and net loss was $42.3 million, or $0.59 per share.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported that on August 3, 2026, its Board Compensation Committee granted non-qualified stock options to purchase an aggregate 84,000 shares of common stock to two newly hired employees under its 2022 Employment Inducement Incentive Award Plan.
The options were issued as material inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4), carry a $4.65 exercise price equal to the grant-date closing price, have a 10-year term, and vest over four years: 25% after one year and the remaining 75% in equal monthly installments over the following three years, subject to continued service.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) will deliver two presentations on its investigational WEE1 inhibitor azenosertib at the ESMO Congress 2026 in Madrid, Spain, on October 23-27, 2026. A rapid oral session will share overall survival data from Part 1b of the Phase 2 DENALI study in platinum-resistant ovarian cancer (PROC).
Zentalis will also present a trial-in-progress poster on ASPENOVA, a Phase 3 randomized study comparing azenosertib monotherapy at 400mg QD 5:2 to standard single-agent chemotherapy in Cyclin E1-positive PROC, designed to support potential accelerated and full approval pathways.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) granted non-qualified stock options to purchase an aggregate of 191,000 shares of common stock to two newly hired employees on June 1, 2026.
The options, issued under the 2022 Employment Inducement Incentive Award Plan, have a $3.98 exercise price, 10-year term, and four-year vesting schedule.